Aquinox Pharmaceuticals (AQXP) Trading Up 10.2%

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)’s share price was up 10.2% during mid-day trading on Friday . The stock traded as high as $11.66 and last traded at $11.31. Approximately 891,085 shares changed hands during mid-day trading, an increase of 897% from the average daily volume of 89,393 shares. The stock had previously closed at $10.26.

Several equities analysts have issued reports on AQXP shares. ValuEngine downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $22.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the period. Archon Partners LLC increased its stake in shares of Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the period. Nexthera Capital LP acquired a new stake in shares of Aquinox Pharmaceuticals in the 2nd quarter valued at $1,276,000. University of Notre Dame DU Lac increased its stake in shares of Aquinox Pharmaceuticals by 11.1% in the 3rd quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after buying an additional 19,066 shares during the period. Finally, Sphera Funds Management LTD. increased its stake in shares of Aquinox Pharmaceuticals by 21.7% in the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after buying an additional 13,450 shares during the period. 96.25% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Trading Up 10.2%” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/15/aquinox-pharmaceuticals-aqxp-trading-up-10-2.html.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit